Skip to contentpdufa.bio

SPY072 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

SPY072 Phase is a Spyre Therapeutics, Inc. program in hidradenitis suppurativa. Its next catalyst is a Readout in Q4 2028.

SYRE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Hidradenitis suppurativa. Sponsor: Spyre Therapeutics, Inc. (SYRE). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2028SYRE

Specialist biotech funds holding SYRE, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments3,691,791$328.7 millionfiled November 16, 2026
Perceptive Advisors3,280,943$292.1 millionfiled November 16, 2026
Cormorant Asset Management125,000$11.1 millionfiled November 16, 2026
OrbiMed Advisors47,326$4.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is SPY072 Phase's next FDA decision or readout?

The next tracked catalyst for SPY072 Phase is a Readout in Q4 2028.

What happened at SPY072 Phase's most recent FDA decision?

No FDA decision for SPY072 Phase is in our archive yet.

What is SPY072 Phase used for?

In our records SPY072 Phase is under review or in development for Hidradenitis suppurativa.

Who makes SPY072 Phase?

Spyre Therapeutics, Inc. (SYRE).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.